Details and outcomes of a large cohort of MOG-IgG associated optic neuritis
Copyright © 2022. Published by Elsevier B.V..
BACKGROUND: The goal of this study was to examine the temporal relationship of eye pain to visual loss and investigate whether timing of steroid treatment affects the rate and extent of visual recovery in optic neuritis (ON) from MOG-IgG associated disease (MOGAD) in a large cohort of MOGAD patients with ON.
METHODS: This is a multicenter, retrospective cohort study of consecutive MOGAD patients with ON attacks seen from 2017 to 2021 fulfilling the following criteria: (1) clinical history of ON; (2) MOG-IgG seropositivity. ON attacks were evaluated for presence/duration of eye pain, nadir of vision loss, time to intravenous methylprednisolone (IVMP) treatment, time to recovery, and final visual outcomes.
RESULTS: There were 107 patients with 140 attacks treated with IVMP and details on timing of treatment and outcomes. Eye pain was present in 125/140 (89%) attacks with pain onset a median of 3 days (range, 0 to 20) prior to vision loss. Among 46 ON attacks treated with IVMP within 2 days of onset of vision loss, median time to recovery was 4 days (range, 0 to 103) compared to 15 days (range, 0 to 365) in 94 ON attacks treated after 2 days (p = 0.004). Those treated within 2 days had less severe VA loss at time of treatment (median LogMAR VA 0.48, range, 0.1 to 3) compared to those treated after 2 days (median LogMAR VA 1.7, range, 0 to 3; p < 0.001), and were more likely to have a VA outcome of 20/40 or better (98% vs 83%, p = 0.01). After adjustment for the initial VA at time of treatment, the differences in final VA were no longer significantly different (p = 0.14). In addition, some patients were documented to recover without steroid treatment.
CONCLUSION: This study suggests that pain precedes vision loss in the majority of ON attacks and early steroids may lead to better outcomes in MOG-IgG ON, but some patients can recover without steroid treatment. Prospective randomized clinical trials are required to confirm these findings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
Multiple sclerosis and related disorders - 68(2022) vom: 01. Dez., Seite 104237 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, John J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.12.2022 Date Revised 21.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.msard.2022.104237 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM347672175 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM347672175 | ||
| 003 | DE-627 | ||
| 005 | 20231226034404.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2022.104237 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1158.xml |
| 035 | |a (DE-627)NLM347672175 | ||
| 035 | |a (NLM)36252317 | ||
| 035 | |a (PII)S2211-0348(22)00741-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, John J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Details and outcomes of a large cohort of MOG-IgG associated optic neuritis |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.12.2022 | ||
| 500 | |a Date Revised 21.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022. Published by Elsevier B.V. | ||
| 520 | |a BACKGROUND: The goal of this study was to examine the temporal relationship of eye pain to visual loss and investigate whether timing of steroid treatment affects the rate and extent of visual recovery in optic neuritis (ON) from MOG-IgG associated disease (MOGAD) in a large cohort of MOGAD patients with ON | ||
| 520 | |a METHODS: This is a multicenter, retrospective cohort study of consecutive MOGAD patients with ON attacks seen from 2017 to 2021 fulfilling the following criteria: (1) clinical history of ON; (2) MOG-IgG seropositivity. ON attacks were evaluated for presence/duration of eye pain, nadir of vision loss, time to intravenous methylprednisolone (IVMP) treatment, time to recovery, and final visual outcomes | ||
| 520 | |a RESULTS: There were 107 patients with 140 attacks treated with IVMP and details on timing of treatment and outcomes. Eye pain was present in 125/140 (89%) attacks with pain onset a median of 3 days (range, 0 to 20) prior to vision loss. Among 46 ON attacks treated with IVMP within 2 days of onset of vision loss, median time to recovery was 4 days (range, 0 to 103) compared to 15 days (range, 0 to 365) in 94 ON attacks treated after 2 days (p = 0.004). Those treated within 2 days had less severe VA loss at time of treatment (median LogMAR VA 0.48, range, 0.1 to 3) compared to those treated after 2 days (median LogMAR VA 1.7, range, 0 to 3; p < 0.001), and were more likely to have a VA outcome of 20/40 or better (98% vs 83%, p = 0.01). After adjustment for the initial VA at time of treatment, the differences in final VA were no longer significantly different (p = 0.14). In addition, some patients were documented to recover without steroid treatment | ||
| 520 | |a CONCLUSION: This study suggests that pain precedes vision loss in the majority of ON attacks and early steroids may lead to better outcomes in MOG-IgG ON, but some patients can recover without steroid treatment. Prospective randomized clinical trials are required to confirm these findings | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a MOG-IgG associated disease | |
| 650 | 4 | |a MOGAD | |
| 650 | 4 | |a Optic neuritis | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a Steroids | |
| 650 | 7 | |a Myelin-Oligodendrocyte Glycoprotein |2 NLM | |
| 650 | 7 | |a Aquaporin 4 |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Methylprednisolone |2 NLM | |
| 650 | 7 | |a X4W7ZR7023 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Flanagan, Eoin P |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatti, M Tariq |e verfasserin |4 aut | |
| 700 | 1 | |a Tisavipat, Nanthaya |e verfasserin |4 aut | |
| 700 | 1 | |a Jamali, Sepideh |e verfasserin |4 aut | |
| 700 | 1 | |a Kunchok, Amy |e verfasserin |4 aut | |
| 700 | 1 | |a Eggenberger, Eric R |e verfasserin |4 aut | |
| 700 | 1 | |a Nome, Marie Di |e verfasserin |4 aut | |
| 700 | 1 | |a Sotirchos, Elias S |e verfasserin |4 aut | |
| 700 | 1 | |a Vasileiou, Eleni S |e verfasserin |4 aut | |
| 700 | 1 | |a Henderson, Amanda D |e verfasserin |4 aut | |
| 700 | 1 | |a Arnold, Anthony C |e verfasserin |4 aut | |
| 700 | 1 | |a Bonelli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Seleme, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Mejia-Vergara, Alvaro J |e verfasserin |4 aut | |
| 700 | 1 | |a Moss, Heather E |e verfasserin |4 aut | |
| 700 | 1 | |a Padungkiatsagul, Tanyatuth |e verfasserin |4 aut | |
| 700 | 1 | |a Stiebel-Kalish, Hadas |e verfasserin |4 aut | |
| 700 | 1 | |a Lotan, Itay |e verfasserin |4 aut | |
| 700 | 1 | |a Wilf-Yarkoni, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Hellmann, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Vuppala, Amrita |e verfasserin |4 aut | |
| 700 | 1 | |a Hodge, David |e verfasserin |4 aut | |
| 700 | 1 | |a Pittock, Sean J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple sclerosis and related disorders |d 2012 |g 68(2022) vom: 01. Dez., Seite 104237 |w (DE-627)NLM219118388 |x 2211-0356 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2022 |g day:01 |g month:12 |g pages:104237 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.msard.2022.104237 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2022 |b 01 |c 12 |h 104237 | ||